S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Spero Therapeutics Stock Price, News & Analysis (NASDAQ:SPRO)

$1.27
-0.02 (-1.55%)
(As of 12/6/2023 ET)
Compare
Today's Range
$1.21
$1.31
50-Day Range
$1.00
$1.29
52-Week Range
$0.99
$2.04
Volume
155,056 shs
Average Volume
357,771 shs
Market Capitalization
$67.31 million
P/E Ratio
127.00
Dividend Yield
N/A
Price Target
$7.00

Spero Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
451.2% Upside
$7.00 Price Target
Short Interest
Healthy
2.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$50,160 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.50) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

256th out of 957 stocks

Biotechnology Industry

12th out of 67 stocks


SPRO stock logo

About Spero Therapeutics Stock (NASDAQ:SPRO)

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

SPRO Stock Price History

SPRO Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Recap: Spero Therapeutics Q3 Earnings
Spero Therapeutics Q3 2023 Earnings Preview
Here's what Wall Street expects from Spero Therapeutics's earnings report
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
4 Analysts Have This to Say About Spero Therapeutics
Q2 2023 Spero Therapeutics Inc Earnings Call
See More Headlines
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
35
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+451.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-46,420,000.00
Pretax Margin
0.77%

Debt

Sales & Book Value

Annual Sales
$53.51 million
Book Value
$1.45 per share

Miscellaneous

Free Float
50,768,000
Market Cap
$67.31 million
Optionable
Optionable
Beta
0.86

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Ankit Mahadevia M.D. (Age 42)
    MBA, Co-Founder & Chairman of the Board
    Comp: $1.24M
  • Mr. Satyavrat Shukla C.F.A. (Age 51)
    President, CEO & Director
    Comp: $823.27k
  • Ms. Tamara Lynn Joseph L.L.M. (Age 60)
    Chief Legal Officer
    Comp: $775.55k
  • Ms. Esther P. Rajavelu (Age 44)
    CFO & Chief Business Officer
  • Mr. Timothy Keutzer (Age 55)
    Chief Operating Officer
  • Ted Jenkins
    VP & Head of Investor Relations
  • Mr. James P. Brady
    Chief Human Resource Officer
  • Dr. Kamal Hamed M.B.A. (Age 62)
    M.D., M.P.H., Chief Medical Officer














SPRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 12 month price targets for Spero Therapeutics' shares. Their SPRO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 451.2% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How have SPRO shares performed in 2023?

Spero Therapeutics' stock was trading at $1.73 at the beginning of 2023. Since then, SPRO stock has decreased by 26.6% and is now trading at $1.27.
View the best growth stocks for 2023 here
.

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its earnings results on Monday, November, 13th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.17. The company earned $25.47 million during the quarter, compared to analysts' expectations of $2.40 million. Spero Therapeutics had a positive trailing twelve-month return on equity of 4.14% and a negative net margin of 2.08%.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (0.63%), Acadian Asset Management LLC (0.52%), Group One Trading L.P. (0.00%), Rock Springs Capital Management LP (0.11%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Kamal Hamed, Sath Shukla and Timothy Keutzer.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SPRO) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -